The results of an ongoing phase 1 first-in-human study of tidutamab, which were presented during the 2021 NANETS Symposium, demonstrated that the bispecific antibody directed toward somatostatin receptor 2 and CD3 was generally well tolerated and elicited 26.8% rate of stable disease in evaluable patients with advanced NETs. Read more . . .
Bassel El-Rayes, MD, director, Gastrointestinal Oncology Program, associate director for clinical research, John Kauffman Family Professor for Pancreatic Cancer Research, Winship Cancer Institute of Emory University, professor and vice chair for clinical research, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the efficacy of tidutamab in advanced neuroendocrine tumors (NETs).